1. 124PAssociation of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). (23rd October 2018) Authors: Miller-Phillips, L; Fischer von Weikersthal, L; Kaiser, F; Al-Batran, S-E; Heintges, T; Neureiter, D; Kahl, C; Kullmann, F; Moehler, M; Scheithauer, W; Vazart, C; Fontaine, K; Held, S; Modest, D P; Neumann, J; Jung, A; Kirchner, T; Heinemann, V; Stintzing, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 509PFactors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): A FIRE-3 analysis. (23rd October 2018) Authors: Modest, D P; Heinemann, V; Folprecht, G; Denecke, T; Pratschke, J; Lang, H; Bemelmans, M; Becker, T; Rentsch, M; Seehofer, D; Bruns, C; Gebauer, B; Held, S; Neumann, U; Ricard, I Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. (14th November 2019) Authors: Stintzing, S; Wirapati, P; Lenz, H -J; Neureiter, D; Fischer von Weikersthal, L; Decker, T; Kiani, A; Kaiser, F; Al-Batran, S; Heintges, T; Lerchenmüller, C; Kahl, C; Seipelt, G; Kullmann, F; Moehler, M; Scheithauer, W; Held, S; Modest, D P; Jung, A; Kirchner, T Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗